Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. ovarenew

OvaRenew

OvaRenew as a first-line therapy in impaired egg quality treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 OvaRenew project word cloud

Explore the words cloud of the OvaRenew project. It provides you a very rough idea of what is the project "OvaRenew" about.

expenditures    9    global    clinical    opportunity    27    suitable    fertility    gmp    manufacturer    science    intend    grab    impaired    human    cell    invasive    safety    health    strategy    ip    phase2    services    world    decreasing    ovarenew    helping    deepest    orally    administered    mio    regulators    expansion    oocytes    practical    quality    trials    complications    regulatory    child    protection    feasibility    infertility    regulated    4    ovarian    invasiveness    final    innovative    worldwide    first    disruptive    assesment    2015    industry    ethics    medica    alignement    drastically    plan    therapy    investment    women    contract    performed    stem    egg    initial    close    nutritive    contracted    solution    rates    business    risk    initiated    36    revolutionize    expensive    tackling    industries    ovaries    substances    potenza    procurement    novelty    ltd    transform    billion    dialogue    specialised    combining    assure    cells    line    genetically    pertaining    elaborated    prepared    market    woman    commercialisation    markets    country    reproduction   

Project "OvaRenew" data sheet

The following table provides information about the project.

Coordinator		 POTENZA MEDICA D.O.O. 

Organization address
address: CESTA CANKARJEVE BRIGADE 18
city: GROSUPLJE
postcode: 1290
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Slovenia [SI]
 Project website http://www.ovarenew.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-12-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    POTENZA MEDICA D.O.O. SI (GROSUPLJE) coordinator 50˙000.00

Map

 Project objective

Potenza Medica Ltd. is specialised in the development and commercialisation of innovative fertility products. Our solution is tackling one of the deepest human needs-reproduction. With OvaRenew as a first-line therapy in ovarian infertility, we intend to grab business opportunity to be the first in the world with disruptive fertility solution for women with impaired egg quality. Global fertility services market was in 2015 estimated to be between 27-36 billion € with growth rates of 8-9% in EU and 4% in US. The novelty is in innovative combining of new findings in fertility and nutritive science, which will revolutionize current industry practice. OvaRenew is based on disruptive findings of stem cells in ovaries that are able to transform into oocytes under defined conditions. Those will be initiated through the substances, administered orally. So far, there is no effective and practical strategy available for impaired egg quality. They all are highly invasive with significant health complications, expensive, not focusing in helping woman to produce genetically own child. OvaRenew will enable women with impaired egg quality to produce their own child while drastically decreasing cost and invasiveness of the procedures on one and country health and other expenditures on the other hand. In 2 years (Phase2), OvaRenew can be prepared for global commercialisation. With 1 mio € investment, final product is planned to be introduced on global markets, with focus on developed world. In Phase 1, a feasibility study will be performed with focus on risk assesment and IP protection. While we are operating in one of the most regulated industries, in close dialogue with regulators, we will assure alignement for safety and regulatory requirements such as those pertaining to cell procurement, GMP, ethics and clinical trials. Suitable contract manufacturer will be contracted. Comprehensive business plan will be elaborated to facilitate initial market up-take and worldwide expansion

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OVARENEW" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OVARENEW" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

INTE-AFRICA (2019)

Integrating and decentralising diabetes and hypertension services in Africa

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More